Table A3.2Baseline incremental cost-effectiveness ratios

CostLYQALYs1QALYs2
WW£61859.696.966.63
RP£1061910.197.526.36
ICER£8868£7918Dominated

RP, Radical Prostatectomy; WW, Watchful Waiting; ICER, incremental cost-effectiveness ratio

In QALYs1, there is 0 probability of complications following treatment whereas in QALYs2, the additional probabilities of urinary obstruction, urinary leakage and impotence are assumed.

From: Appendix 3, An Economic Evaluation of Radical Prostatectomy Versus Alternative Treatment Options for Clinically Localised Prostate Cancer

Cover of Prostate Cancer
Prostate Cancer: Diagnosis and Treatment.
NICE Clinical Guidelines, No. 58.
National Collaborating Centre for Cancer (UK).
Copyright © 2008, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.